• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

非甾体抗炎药对人早期骨关节炎膝关节中尿激酶型纤溶酶原激活剂及其抑制剂和明胶酶表达的影响

Effects of nonsteroidal anti-inflammatory drugs on the expression of urokinase plasminogen activator and inhibitor and gelatinases in the early osteoarthritic knee of humans.

作者信息

Yang Shun-Fa, Hsieh Yih-Shou, Lue Ko-Huang, Chu Shu-Chen, Chang I-Chang, Lu Ko-Hsiu

机构信息

Institute of Medicine, Chung Shan Medical University, Taichung 402, Taiwan.

出版信息

Clin Biochem. 2008 Jan;41(1-2):109-16. doi: 10.1016/j.clinbiochem.2007.10.011. Epub 2007 Oct 26.

DOI:10.1016/j.clinbiochem.2007.10.011
PMID:17996201
Abstract

OBJECTIVES

The purpose of this study was to examine the ex vivo effects of nonsteroidal anti-inflammatory drugs (NSAIDs) on the expression of urokinase-type plasminogen activator (u-PA), PA inhibitor-1 (PAI-1) and gelatinases [matrix metalloproteinase (MMP)-2 and MMP-9] in the early knee osteoarthritis (OA) of humans.

DESIGN AND METHODS

Samples of articular cartilage, meniscus and synovium of OA patients were obtained and cultured ex vivo in the presence or absence of NSAIDs (diclofenac sodium, nimesulide, celecoxib, valdecoxib, rofecoxib and etoricoxib).

RESULTS

Gelatin zymography showed that all NSAIDs generally decreased MMP-2 secretion in chondral, meniscal and synovial cultures as well as MMP-9 production in meniscal and synovial cultures. ELISA showed the inhibitions of u-PA secretion in chondral cultures by diclofenac and rofecoxib as well as in chondral and synovial cultures by nimesulide, celecoxib and etoricoxib at 48 h. On PAI-1 secretion, rofecoxib in synovial cultures and diclofenac, nimesulide, celecoxib and etoricoxib in chondral and synovial cultures had significantly suppressive effects at 48 h.

CONCLUSIONS

This study clearly demonstrates that NSAIDs can down-regulate the PA/plasmin system and gelatinases expression during the early stage of knee OA, thereby possibly affect the structural progression of the disease. This inhibition seems to be independent selection of COX-1 and COX-2.

摘要

目的

本研究旨在探讨非甾体抗炎药(NSAIDs)对人早期膝关节骨关节炎(OA)中尿激酶型纤溶酶原激活剂(u-PA)、PA抑制剂-1(PAI-1)和明胶酶[基质金属蛋白酶(MMP)-2和MMP-9]表达的体外影响。

设计与方法

获取OA患者的关节软骨、半月板和滑膜样本,在有或无NSAIDs(双氯芬酸钠、尼美舒利、塞来昔布、伐地昔布、罗非昔布和依托考昔)存在的情况下进行体外培养。

结果

明胶酶谱分析显示,所有NSAIDs通常都会降低软骨、半月板和滑膜培养物中MMP-2的分泌,以及半月板和滑膜培养物中MMP-9的产生。酶联免疫吸附测定(ELISA)显示,双氯芬酸和罗非昔布在48小时时抑制软骨培养物中u-PA的分泌,尼美舒利、塞来昔布和依托考昔在48小时时抑制软骨和滑膜培养物中u-PA的分泌。关于PAI-1的分泌,罗非昔布在滑膜培养物中以及双氯芬酸、尼美舒利、塞来昔布和依托考昔在软骨和滑膜培养物中在48小时时有显著的抑制作用。

结论

本研究清楚地表明,NSAIDs在膝关节OA早期可下调PA/纤溶酶系统和明胶酶的表达,从而可能影响疾病的结构进展。这种抑制作用似乎与COX-1和COX-2的选择无关。

相似文献

1
Effects of nonsteroidal anti-inflammatory drugs on the expression of urokinase plasminogen activator and inhibitor and gelatinases in the early osteoarthritic knee of humans.非甾体抗炎药对人早期骨关节炎膝关节中尿激酶型纤溶酶原激活剂及其抑制剂和明胶酶表达的影响
Clin Biochem. 2008 Jan;41(1-2):109-16. doi: 10.1016/j.clinbiochem.2007.10.011. Epub 2007 Oct 26.
2
Effects of different molecular weight hyaluronan products on the expression of urokinase plasminogen activator and inhibitor and gelatinases during the early stage of osteoarthritis.不同分子量透明质酸产品对骨关节炎早期尿激酶型纤溶酶原激活剂、抑制剂及明胶酶表达的影响
J Orthop Res. 2008 Apr;26(4):475-84. doi: 10.1002/jor.20524.
3
Upregulation of urokinase-type plasminogen activator and inhibitor and gelatinase expression via 3 mitogen-activated protein kinases and PI3K pathways during the early development of osteoarthritis.骨关节炎早期发育过程中,通过3种丝裂原活化蛋白激酶和PI3K途径上调尿激酶型纤溶酶原激活剂、抑制剂和明胶酶的表达。
J Rheumatol. 2007 Apr;34(4):785-93.
4
Glucosamine sulfate suppresses the expressions of urokinase plasminogen activator and inhibitor and gelatinases during the early stage of osteoarthritis.硫酸氨基葡萄糖在骨关节炎早期抑制尿激酶型纤溶酶原激活剂、抑制剂和明胶酶的表达。
Clin Chim Acta. 2006 Oct;372(1-2):167-72. doi: 10.1016/j.cca.2006.04.014. Epub 2006 Jun 6.
5
Naproxen, meloxicam and methylprednisolone inhibit urokinase plasminogen activator and inhibitor and gelatinases expression during the early stage of osteoarthritis.萘普生、美洛昔康和甲泼尼龙在骨关节炎早期抑制尿激酶型纤溶酶原激活剂、抑制剂及明胶酶的表达。
Clin Chim Acta. 2008 Jan;387(1-2):90-6. doi: 10.1016/j.cca.2007.09.012. Epub 2007 Sep 21.
6
Expression changes of gelatinases in human osteoarthritic knees and arthroscopic debridement.明胶酶在人类骨关节炎膝关节及关节镜清创术中的表达变化
Arthroscopy. 2004 May;20(5):482-8. doi: 10.1016/j.arthro.2004.03.010.
7
Urokinase-type plasminogen activator, receptor, and inhibitor correlating with gelatinase-B (MMP-9) contribute to inflammation in gouty arthritis of the knee.与明胶酶-B(基质金属蛋白酶-9)相关的尿激酶型纤溶酶原激活剂、受体及抑制剂在膝关节痛风性关节炎的炎症中起作用。
J Rheumatol. 2006 Feb;33(2):311-7.
8
Regulation of gelatinases expression by cytokines, endotoxin, and pharmacological agents in the human osteoarthritic knee.细胞因子、内毒素及药物制剂对人骨关节炎膝关节中明胶酶表达的调控
Connect Tissue Res. 2004;45(3):142-50. doi: 10.1080/03008200490506058.
9
Hyaluronic acid inhibits the expression of u-PA, PAI-1, and u-PAR in human synovial fibroblasts of osteoarthritis and rheumatoid arthritis.透明质酸抑制骨关节炎和类风湿关节炎患者滑膜成纤维细胞中尿激酶型纤溶酶原激活物(u-PA)、纤溶酶原激活物抑制剂-1(PAI-1)和尿激酶型纤溶酶原激活物受体(u-PAR)的表达。
J Rheumatol. 2000 Apr;27(4):997-1004.
10
Hemoglobin stimulates the expression of matrix metalloproteinases, MMP-2 and MMP-9 by synovial cells: a possible cause of joint damage after intra-articular hemorrhage.血红蛋白可刺激滑膜细胞表达基质金属蛋白酶MMP - 2和MMP - 9:这可能是关节内出血后关节损伤的一个原因。
J Orthop Res. 2005 Jul;23(4):891-8. doi: 10.1016/j.orthres.2005.01.003. Epub 2005 Mar 2.

引用本文的文献

1
Effectiveness of Bach Nien Kien Health Supplement in the Treatment of Patients With Symptomatic Knee Osteoarthritis.八厘见健保健补充剂治疗有症状的膝骨关节炎的疗效。
In Vivo. 2024 Mar-Apr;38(2):963-970. doi: 10.21873/invivo.13528.
2
Evaluation of the Anti-Inflammatory and Chondroprotective Effect of Celecoxib on Cartilage and in a Rat Osteoarthritis Model.评估塞来昔布对软骨的抗炎和软骨保护作用及其在大鼠骨关节炎模型中的作用。
Cartilage. 2022 Jul-Sep;13(3):19476035221115541. doi: 10.1177/19476035221115541.
3
Proinflammatory cytokines and lipopolysaccharides up regulate MMP-3 and MMP-13 production in Asian elephant (Elephas maximus) chondrocytes: attenuation by anti-arthritic agents.
促炎细胞因子和脂多糖上调亚洲象(Elephas maximus)软骨细胞中 MMP-3 和 MMP-13 的产生:抗关节炎药物的抑制作用。
BMC Vet Res. 2019 Nov 21;15(1):419. doi: 10.1186/s12917-019-2170-8.
4
Association between the polymorphisms of urokinase plasminogen activation system and cancer risk: a meta-analysis.尿激酶纤溶酶原激活系统多态性与癌症风险的关联:荟萃分析。
Onco Targets Ther. 2015 Sep 9;8:2493-502. doi: 10.2147/OTT.S85520. eCollection 2015.
5
Establishment of a rat model of lumbar facet joint osteoarthritis using intraarticular injection of urinary plasminogen activator.通过关节内注射尿激酶型纤溶酶原激活剂建立大鼠腰椎小关节骨关节炎模型。
Sci Rep. 2015 Apr 20;5:9828. doi: 10.1038/srep09828.
6
The anti-inflammatory effect of cyclooxygenase inhibitors in fibroblast-like synoviocytes from the human temporomandibular joint results from the suppression of PGE2 production.环氧化酶抑制剂在人颞下颌关节成纤维样滑膜细胞中的抗炎作用源于对 PGE2 生成的抑制。
J Oral Pathol Med. 2013 Jul;42(6):499-506. doi: 10.1111/jop.12045. Epub 2013 Jan 18.
7
Recent progress in understanding molecular mechanisms of cartilage degeneration during osteoarthritis.骨关节炎中软骨退变分子机制的研究进展。
Ann N Y Acad Sci. 2011 Dec;1240:61-9. doi: 10.1111/j.1749-6632.2011.06258.x.
8
Celecoxib: considerations regarding its potential disease-modifying properties in osteoarthritis.塞来昔布:关于其在骨关节炎中潜在的疾病修饰作用的考虑。
Arthritis Res Ther. 2011;13(5):239. doi: 10.1186/ar3437. Epub 2011 Sep 21.
9
Mechanisms of non-opioid analgesics beyond cyclooxygenase enzyme inhibition.非阿片类镇痛药除了抑制环氧化酶以外的作用机制。
Curr Mol Pharmacol. 2009 Jan;2(1):1-14. doi: 10.2174/1874467210902010001.
10
Etoricoxib: a review of its use in the symptomatic treatment of osteoarthritis, rheumatoid arthritis, ankylosing spondylitis and acute gouty arthritis.依托考昔:用于骨关节炎、类风湿关节炎、强直性脊柱炎及急性痛风性关节炎症状性治疗的综述
Drugs. 2009 Jul 30;69(11):1513-32. doi: 10.2165/00003495-200969110-00008.